PHARMOS NDA FILING FOR FIRST PRODUCT, LENOXIN
Executive Summary
PHARMOS NDA FILING FOR FIRST PRODUCT, LENOXIN, is projected for late 1994. The corticosteroid is designed for treatment of conjunctivitis associated with contact lens wear and allergies; results from Phase III clinical studies were presented by Phannos at an April 27 press conference in New York City. The Phase III results indicate that Lenoxin (lotepredol etabonate) has a lower incidence of side effects -- primarily elevated intraocular pressure -- compared to ophthalmic steroids now on the market, such as prednisolone and dexamethasone.